THE EFFECT OF OMALIZUMAB ON CERTAIN CYTOKINES IN THE TREATMENT OF SEVERE BRONCHIAL ASTHMA

Kireev V. V.; Suyarov A. A.; Musakhodjaeva D. A.; Yuldashev I. R.; Abdullaev N. Ch.; Ochilov S. N.; Erkinov N. G.

Authors

Kireev V. V. Institute of Immunology and Human Genomics of the Academy of Sciences of the Re-public of Uzbekistan
Suyarov A. A. Institute of Immunology and Human Genomics of the Academy of Sciences of the Re-public of Uzbekistan
Musakhodjaeva D. A. Institute of Immunology and Human Genomics of the Academy of Sciences of the Re-public of Uzbekistan
Yuldashev I. R. Tashkent State Medical University
Abdullaev N. Ch. Tashkent State Medical University
Ochilov S. N. Institute of Immunology and Human Genomics of the Academy of Sciences of the Re-public of Uzbekistan
Erkinov N. G. Institute of Immunology and Human Genomics of the Academy of Sciences of the Re-public of Uzbekistan

Keywords:

Bronchial asthma, Omalizumab, interleukins.

Abstract

The article examines the effect of anti-IgE therapy (Omalizumab) on the systemic level of key interleukins (IL 1, IL 2, IL 4, IL 6, IL 10, IL 18) in patients with severe uncontrolled asthma. The role of the drug in the modulation of Th2-dependent inflammation and restoration of im-mune homeostasis is analyzed. The aim of the study was to study the effect of Omalizumab on the level of certain cy-tokines in severe asthma. Materials and methods. 35 patients with severe asthma were examined. The level of cytokines in peripheral blood IL-1, IL-2, IL-4, IL-6, IL-10 and IL-18 was determined before and 2 weeks after administration of Xolar (Omalizumab) at a dose of 150 mg. Results. When Omalizumab was administered, there was a significant increase in the levels of IL 2, IL 10, and IL 18. Conclusions. Omalizumab therapy has a complex effect on cytokines, a new profile of patients with severe asthma.